Your browser doesn't support javascript.
The neutralization of B.1.617.1 and B.1.1.529 sera from convalescent patients and BBIBP-CorV vaccines.
Yang, Xinyi; Zhu, Yuqi; Xun, Jingna; Liu, Jun; Wen, Qing; Lin, Yixiao; Shen, Xiaoting; Chen, Jun; Yuan, Songhua; Zhao, Xiaying; Wang, Jing; Pan, Hanyu; Yang, Jinlong; Liang, Zhiming; Liang, Yue; Lin, Qinru; Liang, Huitong; Zhou, Chunyan; Jin, Li; Xie, Weijian; Liu, Jianping; Lu, Daru; Ying, Tianlei; Shen, Yinzhong; Zhang, Xiaoyan; Xu, Jianqing; Yin, Chunhua; Wang, Pengfei; Jiang, Shibo; Lu, Hongzhou; Zhu, Huanzhang.
  • Yang X; State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai 200438, China.
  • Zhu Y; State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai 200438, China.
  • Xun J; State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai 200438, China.
  • Liu J; Scientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
  • Wen Q; State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai 200438, China.
  • Lin Y; Fubio (Suzhou) Biomedical Technology Co., Ltd, Suzhou, China.
  • Shen X; State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai 200438, China.
  • Chen J; Department of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
  • Yuan S; State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai 200438, China.
  • Zhao X; Department of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
  • Wang J; Scientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
  • Pan H; State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai 200438, China.
  • Yang J; State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai 200438, China.
  • Liang Z; State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai 200438, China.
  • Liang Y; State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai 200438, China.
  • Lin Q; State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai 200438, China.
  • Liang H; State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai 200438, China.
  • Zhou C; State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai 200438, China.
  • Jin L; State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai 200438, China.
  • Xie W; Fubio (Suzhou) Biomedical Technology Co., Ltd, Suzhou, China.
  • Liu J; Fubio (Suzhou) Biomedical Technology Co., Ltd, Suzhou, China.
  • Lu D; Fubio (Suzhou) Biomedical Technology Co., Ltd, Suzhou, China.
  • Ying T; State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai 200438, China.
  • Shen Y; State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai 200438, China.
  • Zhang X; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai, China.
  • Xu J; Department of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
  • Yin C; Scientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
  • Wang P; Scientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
  • Jiang S; State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai 200438, China.
  • Lu H; State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai 200438, China.
  • Zhu H; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai, China.
iScience ; 25(9): 105016, 2022 Sep 16.
Article in English | MEDLINE | ID: covidwho-2004159
ABSTRACT
The SARS-CoV-2 variants B.1.617.1 (Kappa) contain multiple mutations in the spike protein. However, the effect of B.1.617.1 lineage-related mutants on viral infectivity and inactivated-virus vaccine efficacy remains to be defined. We therefore constructed 12 B.1.617.1-related pseudoviruses and systematically studied the effects of mutations on virus infectivity and neutralization resistance to convalescent and inactivated virus vaccine sera. Our results show that the B.1.617.1 variant exhibited both higher infectivity and neutralization resistance in sera at 1 or 3 months after vaccination of 28 individuals and at 14 and 200 days after discharge of 15 convalescents. Notably, 89% of vaccines and 100% of the convalescent serum samples showed more than 2.5-fold reduction in neutralization against one single mutation E484Q. Besides, we found a significant decrease in neutralizing activity in convalescent patients and BBIBP-CorV vaccines for B.1.1.529. These findings demonstrate that inactivated-virus vaccination or convalescent sera showed reduced, but still significant, neutralization against the B.1.617.1 variant.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines / Variants Language: English Journal: IScience Year: 2022 Document Type: Article Affiliation country: J.isci.2022.105016

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines / Variants Language: English Journal: IScience Year: 2022 Document Type: Article Affiliation country: J.isci.2022.105016